Total Payments
$1.3M
2024 Payments
$323,836
Companies
29
Transactions
827
Medicare Patients
308
Medicare Billing
$9,935
Payment Breakdown by Category
Consulting$631,802 (47.5%)
Other$356,582 (26.8%)
Travel$234,441 (17.6%)
Research$91,100 (6.9%)
Food & Beverage$13,640 (1.0%)
Education$1,357 (0.1%)
Gifts$35.87 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $631,802 | 176 | 47.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $264,228 | 168 | 19.9% |
| Travel and Lodging | $234,441 | 196 | 17.6% |
| Honoraria | $91,661 | 22 | 6.9% |
| Unspecified | $91,100 | 59 | 6.9% |
| Food and Beverage | $13,640 | 190 | 1.0% |
| Education | $1,357 | 3 | 0.1% |
| Grant | $693.40 | 1 | 0.1% |
| Gift | $35.87 | 12 | 0.0% |
Payments by Type
General
$1.2M
768 transactions
Research
$91,100
59 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $236,563 | 170 | $0 (2024) |
| GENZYME CORPORATION | $142,495 | 83 | $0 (2024) |
| HEMA Biologics, LLC | $141,868 | 137 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $133,425 | 59 | $0 (2024) |
| F. Hoffmann-La Roche AG | $105,060 | 62 | $0 (2024) |
| Novo Nordisk Inc | $66,678 | 25 | $0 (2022) |
| PFIZER INC. | $59,116 | 32 | $0 (2024) |
| Spark Therapeutics, Inc. | $56,071 | 20 | $0 (2021) |
| Novo Nordisk Health Care AG | $43,272 | 17 | $0 (2024) |
| Genentech USA, Inc. | $42,184 | 56 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $323,836 | 173 | BioMarin Pharmaceutical Inc. ($71,415) |
| 2023 | $241,024 | 161 | HEMA Biologics, LLC ($79,318) |
| 2022 | $202,445 | 137 | CSL Behring ($64,070) |
| 2021 | $126,453 | 87 | CSL Behring ($18,845) |
| 2020 | $111,670 | 47 | F. Hoffmann-La Roche AG ($40,284) |
| 2019 | $152,004 | 104 | Novo Nordisk Inc ($53,528) |
| 2018 | $116,975 | 73 | Shire North American Group Inc ($23,418) |
| 2017 | $54,551 | 45 | Novo Nordisk AS ($17,423) |
All Payment Transactions
827 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $3,315.70 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $1,576.20 | Research |
| Study: An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors • Category: Hematology | ||||||
| 12/12/2024 | Novo Nordisk Health Care AG | Novoeight (Drug) | Consulting Fee | Cash or cash equivalent | $595.00 | General |
| Category: Hemophilia | ||||||
| 12/10/2024 | BioMarin Pharmaceutical Inc. | ROCTAVIAN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Hemophilia A | ||||||
| 12/10/2024 | CSL Behring | — | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| 12/10/2024 | CSL Behring | — | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| 12/09/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $138.14 | General |
| 12/08/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $106.67 | General |
| Category: Hematology | ||||||
| 12/07/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| 12/06/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Mortality in Congenital Hemophilia A - A Systemic Literature Review | F. Hoffmann-La Roche AG | $12,315 | 1 |
| ESTIMATING THE RISK OF THROMBOTIC EVENTS IN PEOPLE WITH CONGENITAL HEMOPHILIA A USING US CLAIMS DATA | F. Hoffmann-La Roche AG | $6,246 | 1 |
| ESTIMATING THE RISK OF THROMBOTIC EVENTS IN PERSONS WITH CONGENITAL HEMOPHILIA A USING US CLAIMS DATA | F. Hoffmann-La Roche AG | $5,575 | 1 |
| An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | F. Hoffmann-La Roche AG | $5,340 | 4 |
| Application of a hemophilia mortality framework to the Emicizumab Global Safety Database | F. Hoffmann-La Roche AG | $5,191 | 1 |
| STUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD of Emicuzumab in mild or moderate Hemophilia A NI | F. Hoffmann-La Roche AG | $5,179 | 1 |
| A systematic review of mortality statistics and causes of death in people with congenital hemophilia A PwcHA | F. Hoffmann-La Roche AG | $4,760 | 2 |
| HemeB Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $4,673 | 4 |
| Emicizumab is well-tolerated and effective in people with congenital hemophilia A regardless of age severity of disease or inhibitor status: a scoping review | F. Hoffmann-La Roche AG | $4,318 | 1 |
| Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis | F. Hoffmann-La Roche AG | $3,931 | 1 |
| Immune Tolerance Induction Study | Biogen, Inc. | $3,710 | 1 |
| Establishment of a Framework for Assessing Mortality in Persons with Congenital Hemophilia A and its Application to an Adverse Event Reporting Database | F. Hoffmann-La Roche AG | $3,536 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRI | F. Hoffmann-La Roche AG | $3,359 | 2 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors | F. Hoffmann-La Roche AG | $3,163 | 4 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors | F. Hoffmann-La Roche AG | $2,861 | 2 |
| ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX | GENZYME CORPORATION | $2,750 | 5 |
| ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX | GENZYME CORPORATION | $2,250 | 6 |
| Phase III Inhibitor Study | F. Hoffmann-La Roche AG | $2,070 | 1 |
| AN OPEN-LABEL EXTENSION STUDY OF SUBCUTANEOUSLY ADMINISTERED FITUSIRAN IN PATIENTS WITH MODERATE OR SEVERE HEMOPHILIA A OR B WHO HAVE PARTICIPATED IN A PREVIOUS CLINICAL STUDY WITH FITUSIRAN | GENZYME CORPORATION | $1,500 | 4 |
| A contemporary framework for understanding mortality in people with congenital hemophilia A PwcHA | F. Hoffmann-La Roche AG | $1,428 | 2 |
| Comparative Global Field Study: Impact of Laboratory Assay Variability on the Assessment of BIVV001 Activity in Clinical Hemostasis Laboratories | GENZYME CORPORATION | $1,250 | 1 |
| COMPREHENSIVE EXAMINATION AND ESTABLISHMENT OF A FRAMEWORK FOR THE ASSESSMENT OF ALL-CAUSE MORTALITY IN CONGENITAL HEMOPHILIA A | F. Hoffmann-La Roche AG | $805.38 | 1 |
| An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With ALN-AT3SC | GENZYME CORPORATION | $750.00 | 2 |
| Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study | F. Hoffmann-La Roche AG | $700.87 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS Q4W IN PATIENTS WITH HEMOPHILIA A | F. Hoffmann-La Roche AG | $700.00 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL | F. Hoffmann-La Roche AG | $683.27 | 2 |
| Retrospective chart review of hemophilia A patients with inhibitors treated with rFVIIIFc for ITI | BIOVERATIV THERAPEUTICS INC. | $648.26 | 2 |
| Understanding fatalities in persons with congenital hemophilia A PwcHA development of a contemporary framework and application using the FAERS database | F. Hoffmann-La Roche AG | $506.11 | 1 |
| NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Effectiveness of starting emicizumab in routine clinical practice for patients with severe hemophilia A without FVIII inhibitor: results using PicnicHealth data in the United States | F. Hoffmann-La Roche AG | $323.18 | 1 |
| EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7 | F. Hoffmann-La Roche AG | $247.36 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 64 | 66 | $5,670 | $1,663 |
| 2022 | 1 | 90 | 105 | $8,295 | $2,970 |
| 2021 | 1 | 73 | 82 | $6,557 | $2,453 |
| 2020 | 1 | 81 | 93 | $7,281 | $2,849 |
Total Patients
308
Total Services
346
Medicare Billing
$9,935
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2023 | 64 | 66 | $5,670 | $1,663 | 29.3% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2022 | 90 | 105 | $8,295 | $2,970 | 35.8% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2021 | 73 | 82 | $6,557 | $2,453 | 37.4% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2020 | 81 | 93 | $7,281 | $2,849 | 39.1% |
About Dr. Steven Pipe, MD
Dr. Steven Pipe, MD is a Pediatric Hematology-Oncology healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255341889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Pipe, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $323,836 received in 2024. These payments were reported across 827 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($631,802).
As a Medicare-enrolled provider, Pipe has provided services to 308 Medicare beneficiaries, totaling 346 services with total Medicare billing of $9,935. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatrics
- Location Ann Arbor, MI
- Active Since 08/08/2006
- Last Updated 09/28/2020
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1255341889
Products in Payments
- SevenFact (Biological) $141,787
- HEMGENIX (Biological) $73,452
- HEMLIBRA (Biological) $73,251
- Hemlibra (Biological) $65,426
- NO PRODUCT DISCUSSED (Drug) $22,534
- BENEFIX (Biological) $17,100
- ROCTAVIAN (Drug) $14,982
- ADVATE (Biological) $14,620
- NovoSeven (Biological) $13,840
- NovoSeven RT (Drug) $12,968
- ADYNOVATE (Biological) $11,692
- Idelvion (Biological) $11,022
- Afstyla (Biological) $8,224
- Non-Covered Product (Drug) $8,182
- FITUSIRAN (Drug) $7,413
- Novoeight (Drug) $4,430
- VONVENDI (Biological) $3,600
- Hemgenix (Biological) $3,037
- REBINYN (Drug) $2,917
- NUWIQ (Biological) $2,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Ann Arbor
Angela Weyand, M.d, M.D
Pediatric Hematology-Oncology — Payments: $367,669
Pediatric Hematology-Oncology $367,669
Patrick Grohar, Md, Phd, MD, PHD
Pediatric Hematology-Oncology — Payments: $7,630
Pediatric Hematology-Oncology $7,630
Santhosh Upadhyaya, Md, MD
Pediatric Hematology-Oncology — Payments: $1,774
Pediatric Hematology-Oncology $1,774
Mark Vander Lugt, M.d, M.D
Pediatric Hematology-Oncology — Payments: $1,042
Pediatric Hematology-Oncology $1,042
Dr. Jennifer Agrusa, M.d, M.D
Pediatric Hematology-Oncology — Payments: $915.73
Pediatric Hematology-Oncology $915.73
Dr. John Prensner, Md, Phd, MD, PHD
Pediatric Hematology-Oncology — Payments: $243.36
Pediatric Hematology-Oncology $243.36